International Journal of Cardiology
Volume 135, Issue 3 , Pages 361-369 , 10 July 2009

The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation

  • Dionyssios I. Leftheriotis

      Affiliations

    • “Attikon” University Hospital of Athens, Department of Cardiology, Athens, Greece
    • Corresponding Author InformationCorresponding author. 1 Rimini street, Haidari, Athens, 12462, Greece. Tel.: +302105832355; fax: +302105832351.
    • ,
  • Katerina T. Fountoulaki

      Affiliations

    • “Attikon” University Hospital of Athens, Department of Cardiology, Athens, Greece
    • ,
  • Panayota G. Flevari

      Affiliations

    • “Attikon” University Hospital of Athens, Department of Cardiology, Athens, Greece
    • ,
  • John T. Parissis

      Affiliations

    • “Attikon” University Hospital of Athens, Department of Cardiology, Athens, Greece
    • ,
  • Fotis K. Panou

      Affiliations

    • “Attikon” University Hospital of Athens, Department of Cardiology, Athens, Greece
    • ,
  • Ioanna T. Andreadou

      Affiliations

    • University of Athens, School of Pharmacy, Department of Pharmaceutical, Chemistry, Athens, Greece
    • ,
  • Koula S. Venetsanou

      Affiliations

    • “KAT” General Hospital, Department of Biochemistry, Athens, Greece
    • ,
  • Efstathios K. Iliodromitis

      Affiliations

    • “Attikon” University Hospital of Athens, Department of Cardiology, Athens, Greece
    • ,
  • Dimitrios Th. Kremastinos

      Affiliations

    • “Attikon” University Hospital of Athens, Department of Cardiology, Athens, Greece

Received 13 July 2007 ,Revised 6 February 2008 ,Accepted 4 April 2008.

References 

  1. Goette A, Lendeckel U, Klein HU. Signal transduction systems and atrial fibrillation. Cardiovasc Res. 2002;54:247–258
  2. Leftheriotis DI, Theodorakis GN, Poulis D, et al. The effects of 5-HT4 receptor blockade and stimulation, during six hours of atrial fibrillation. Europace. 2005;7:560–568
  3. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96:3542–3548
  4. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias. Inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886–2891
  5. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180–1191
  6. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104:174–180
  7. Shiroshita-Takeshita A, Brundel B, Lavoie J, Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res. 2006;69:865–875
  8. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial- tachycardia remodeling in dogs. Circulation. 2004;110:2313–2319
  9. Fuster V, Ryden LE, Cannom DS, et al. Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J. 2001;22:1852–1923
  10. Halligan SC, Gersh BJ, Brown RD, et al. The natural history of lone atrial fibrillation. Ann Intern Med. 2004;140:265–268
  11. Lang RM, et al. on behalf of the Chamber Quantification Writing Group Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–1463
  12. Berkowitsch A, Greiss H, Vukajlovic D, et al. Usefulness of atrial fibrillation burden as a predictor for success of pulmonary vein isolation. Pacing Clin Electrophysiol. 2005;28:1292–1301
  13. Darbar D, Roden DM. Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. Heart Rhythm. 2005;2:544–549
  14. Euler DE, Freidman PA. Atrial arrhythmia burden as an endpoint in clinical trials: is the best surrogate? Lessons from a multicenter defibrillator trial. Card Electrophysiol Rev. 2003;7:355–358
  15. Goette A, Arndt M, Rocken C, et al. Calpains and cytokines in fibrillating human atria. Am J Physiol Heart Circ Physiol. 2002;283:H264–H272
  16. Cordis GA, Maulik N, Das DK. Detection of oxidative stress in heart by estimating the dinitrophenylhydrazine derivative malonaldehyde. J Mol Cell Cardiol. 1995;27:1645–1653
  17. Andreadou I, Iliodromitis EK, Tsovolas K, et al. Acute administration of vitamin E triggers preconditioning via K(ATP) channels and cyclic-GMP without inhibiting lipid peroxidation. Free Radic Biol Med. 2006;41:1092–1099
  18. Maixent JM, Paganelli F, Scaglione J, Levy S. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:612–617
  19. von Haehling S, Jankowska EA, Anker SD. Tumor necrosis factor-a and the failing heart. Pathophysiology and therapeutic implications. Basic Res Cardiol. 2004;99:18–28
  20. Tveit A, Seljeflot I, Grundvold I, et al. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007;99:1544–1548
  21. Saba S, Janczewski AM, Baker LC, et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-a. Am J Physiol Heart Circ Physiol. 2005;289:H1456–H1467
  22. Ishida K, Kimura F, Imamaki M, et al. Relation of inflammatory cytokines to atrial fibrillation after off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg. 2006;29:501–505
  23. Adamopoulos S, Parissis J, Kremastinos DT. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail. 2001;3:517–526
  24. Stouthard JM, Romijn JA, Van der Poll T, et al. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol. 1995;268:E813–E819
  25. Dimmer C, Tavernier R, Gjorgov N, Van Nooten G, Glement DL, Jordaens L. Variations of autonomic tone preceding onset of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 1998;82:22–25
  26. Moore KW, de Waal Malefyt R, Caffman RL, O'Garra A. Inteleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765
  27. Chen MC, Chang HW, Juang SS, et al. Percutaneous transluminal mitral valvuloplasty reduces circulating vascular cell adhesion molecule-1 in rheumatic mitral stenosis. Chest. 2004;125:1213–1217
  28. Mihm MJ, Coyle C, Schanbacher BL, et al. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res. 2001;49:798–807
  29. Barouch LA, Harrison RW, Skaf MW, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature. 2002;416:337–339
  30. Anderson JL, Allen Maycock CA, Lappe DL, et al. Intermountain Heart Collaborative Study group Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol. 2004;94:1255–1259
  31. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006–3010
  32. Ellinor PT, Low A, Patton KK, Shea MA, MacRae CA. C-reactive protein in lone atrial fibrillation. Am. J. Cardiol. 2006;97:1346-1250
  33. Flaker GC, Fletcher KA, Rothbart RM, Halperin JL, Hart RG. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) investigators. Am J Cardiol. 1995;76:355–358
  34. Olshansky B, Heller EN, Mitchell LB, et al. Results from the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. J Am Coll Cardiol. 2005;45:2026–2033
  35. Antonielli E, Pizzuti A, Palinkas A, et al. Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2002;39:1443–1449
  36. Tanabe T, Deguchi Y, Handa S, Takahashi A, Fukushi H. Longer longitudinal atrial dimension in patients with idiopathic paroxysmal atrial fibrillation: a possible cause of atrial fibrillation. Am Heart J. 2001;142:669–678
  37. Cui Q, Zhang W, Wang H, et al. Left and right atrial size and the occurrence predictors in patients with paroxysmal atrial fibrillation. Int J Cardiol. 2008;130:69–71
  38. Mattioli AV, Bonatti S, Bonetti L, Mattioli G. Left atrial size after cardioversion for atrial fibrillation: effect of external direct current shock. J Am Soc Echocardiogr. 2003;16:271–276
  39. Mattioli AV, Sansoni S, Lucchi GR, Mattioli G. Serial evaluation of left atrial dimension after cardioversion for atrial fibrillation and relation to atrial function. Am J Cardiol. 2000;85:832–836

PII: S0167-5273(08)00563-9

doi: 10.1016/j.ijcard.2008.04.012

International Journal of Cardiology
Volume 135, Issue 3 , Pages 361-369 , 10 July 2009

Article Tools

* Image Usage & Resolution